For patients with multiple myeloma receiving bispecific antibodies who have had a slightly extended treatment interval beyond what the FDA label specifies, is repeat step-up dosing clinically necessary, or are there situations where it can be safely omitted?

The data underpinning this label is what was done based on protocols that were written before much of the pharmacokinetics was known, and certainly before a pharmaceutical company was willing to adjust these safety practices; they would be severely financially penalized if safety events disrupt drug...

Within the clinical trials, repeated step-up dosing was suggested if patients had an extended treatment-free interval. The definition of an extended free interval varies between bispecific antibodies, and depending on the time (e.g., >28 days through to >84 days), the recommendation is to either rep...

This is a question that is relatively devoid of data to help guide decision-making. However, for patients who have a treatment interval that is slightly extended beyond the "safe" interval for administration of a bispecific antibody, my experience is that repeating step-up dosing is usually not nece...